Member Info for Matml74

"The Department of Health and Social Care (DHSC) has agreed contracts with:

Omega Diagnostics, headquartered in Alva in Scotland
Global Access Diagnostics, based in Thurleigh

to provide manufacturing capacity for up to 200 million COVID-19 lateral flow antigen tests, which detect positive cases quickly – in under 30 minutes – meaning positive cases can isolate immediately, breaking chains of transmission."

Bella,

No thats not correct. GAD and ODX have the contract to supply the sovereign UK LFD's. It's in the link I shared.

Abingdon/BBI do not have any contract for the sovereign LFD. They are part of UKRTC but that is producing antibody test not antigen LFD's.

You are correct in that GAD will also supply Avacta test to low income countries.

IMO. GAD have the UK sovereign test manufacturing contract and will be making the sovereign test (Avacta).

https://www.gov.uk/government/news/uk-government-announces-partnership-with-british-rapid-test-manufacturers

It seems to me that BBI and Abingdon and possibly Medusa will be manufacturing for private/ROW sales.

There's a little Aussie company called BHP that can help out.

LOL. Sure you have.

Really great news. Interesting he mentions GAD rather than Mologic and we know they have £billion + contract with the government to manufacture UK’s sovereign LFD’s.

Beast, You normally wouldn't on an AIM share but for some reason back in October this share was moved onto SETS which allows auto trading.

Beast, This method of many small trades is generally used by high frequency traders (HFT) mainly. There is some details in the link below but it is a way of triggering algorithm trades.

https://www.investopedia.com/articles/active-trading/092114/strategies-and-secrets-high-frequency-trading-hft-firms.asp

Agree Andy. We don't know what is going on in the background with Activ/FDA. I am sure if there is any kind of positive data out of HT discussions will be going on with them and when the HT data is released will be an irrelevance.

Maver1k, It shouldn't take long but the data analysis is done externally so depends on how busy they are.

A paper looking at viral entry to cells.

“In this study, we provide evidence that IFITM2 has potent inhibitory activity against SARS-CoV-2 entry and constitutes at least part of the antiviral activity conferred by treatment of target cells with IFN-ß.”

“Studies from many groups have shown that while SARS-CoV-2 is a poor inducer of IFN responses in infected cells early in the replication cycle, it is highly sensitive to pretreatment of target cells by type I, II, and III IFNs (17, 18, 38). This suggests the potential for multiple ISGs to restrict SARS-CoV-2 replication and has raised the possibility of IFNs as possible treatments for COVID-19 (39). The role of IFNs in SARS-CoV-2 pathogenesis is complex. Genetic lesions in pattern recognition and IFN signaling as well as serum autoantibodies that neutralize type I IFNs are associated with risk of severe coronavirus disease 2019 (COVID-19) (40). However, dysregulated or delayed IFN responses driving systemic inflammation may underlie some of the pathology in COVID-19 (41). Understanding which aspects of the IFN response are antiviral against SARS-CoV-2 is thus of very high importance.”

https://jvi.asm.org/content/95/9/e02422-20

Not long now Schrow. Exciting few weeks coming up.

Treatment for severe covid of patient with autoantibodies of type 1 INF.

“ Type I interferons (IFNs) are crucial in protecting against severe coronavirus disease 2019 (COVID-19), and a high percentage of patients with life-threatening COVID-19 either carry loss-of-function variants in the genes for type I IFNs or neutralizing autoantibodies (aAbs) against type I IFNs.1,2 This is in agreement with observations that the IFN response is important in limiting the early viremic phase of the disease, as well as for the subsequent resolution of inflammation.3 Removal of aAbs through plasmapheresis has been suggested as a targeted treatment in severe COVID-19 with concomitant type I IFN aAbs.”

https://www.jacionline.org/article/S0091-6749(21)00556-X/fulltext

Interferon Stimulated Genes!

https://www.sbpdiscovery.org/news/covid-19-scientists-identify-human-genes-fight-infection

Just had this from my son’s school. LFD’s doing their job.

“ We have been advised by Public Health England that there has been a confirmed case of COVID-19 within the school.

We know that you may find this concerning but we are continuing to monitor the situation and are working closely with Public Health England. This letter is to inform you of the current situation and provide advice on how to support your child. Please be reassured that for most people, coronavirus (COVID-19) will be a mild illness.

The small number of children who have been in close contact with the individual who has tested positive for coronavirus (COVID-19) have received a letter informing them that their child must stay at home for 10 days.

The school remains open and your child should continue to attend as normal if they remain well.”

All we need now is a test that doesn’t bring tears to the kids eyes every time they use them!

New paper

“ Patients with severe COVID-19 also show impaired interferon type I response, which is associated with a persistent blood viral load (appendix p 1)”

”This is a viral disease, not an autoimmune one. In conclusion, the available evidence would support combined strategies to simultaneously control viral replication and deleterious inflammation, based on specific indicators or biomarkers of both pathophysiological processes. Effective antiviral treatments are nonetheless needed to achieve this goal.”

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00084-7/fulltext

*by viruses

A good article here on asymptomatic infection of viruses.

https://www.theatlantic.com/science/archive/2021/04/why-coronavirus-can-infect-us-without-making-us-sick/618530/

Good to see this Iranian study published with further positive data on INF B.

Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial

https://www.nature.com/articles/s41598-021-86859-y

“ In patients with laboratory-confirmed SARS-CoV-2 infection, as compared with the base therapeutic regiment, the benefit of a significant reduction in TTCI was observed in the IFNß1a arm. This finding needs further confirmation in larger studies.”

Just paying for the website upgrade.